Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching

Source: Article title. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching

Cohort study · Scientific Reports · 2017

Original publication title

Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching

Yoshitsugu Obi; Takayuki Hamano; Atsushi Wada; Yoshiharu Tsubakihara; The Committee of Renal Data Registry of the Japanese Society for Dialysis TherapyNakaiShigeru6HanafusaNorio7MasakaneIkuto8ItamiNoritomo9YamagataKunihiro10ShinodaToshio11KazamaJunichiro James12WatanabeYuzo13ShigematsuTakashi14MarubayashiSeiji15MoritaOsamu16KimataNaoki17WakaiKenji18OgataSatoshi19IsekiKunitoshi20YamamotoKeiichi21ShintaniAyumu22

Copyright © 2017, The Author(s)

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Vitamin D receptor activators (VDRA) may exert pleiotropic effects on cardiovascular disease, malignancy, and infections among dialysis patients, but recent studies have mainly focused on cardiovascular outcomes. Among 8,675 patients who started dialysis in 2007 and who survived until January 1, 2010, listed in the Renal Data Registry of the Japanese Society for Dialysis Therapy, 5,365 VDRA users were matched to 3,203 non-users based on clinically relevant variables at the end of 2009 using the coarsened exact matching procedure. Until December 31, 2011, a total of 1,128 deaths occurred, of which 468 (42%) were cardiovascular deaths, 229 (20%) were infection-related deaths, and 141 (12%) were malignancy-related deaths.

Multivariable survival analyses accounting for intra-region correlation revealed that VDRA use was significantly associated with lower rates of infection: and malignancy-related deaths [subhazard ratio 0.62 (95% CI, 0.52 to 0.73) and 0.70 (95% CI, 0.50 to 0.97), respectively] but not with cardiovascular death [subhazard ratio 0.86 (95% CI, 0.72 to 1.04)]. Future randomized clinical trials with a sufficient sample size and an adequate follow-up period are warranted to test the clinical effectiveness of VDRA on infection and malignancy, rather than cardiovascular disease, among dialysis patients.

Authors’ abstract

Vitamin D receptor activators (VDRA) may exert pleiotropic effects on cardiovascular disease, malignancy, and infections among dialysis patients, but recent studies have mainly focused on cardiovascular outcomes. Among 8,675 patients who started dialysis in 2007 and who survived until January 1, 2010, listed in the Renal Data Registry of the Japanese Society for Dialysis Therapy, 5,365 VDRA users were matched to 3,203 non-users based on clinically relevant variables at the end of 2009 using the coarsened exact matching procedure. Until December 31, 2011, a total of 1,128 deaths occurred, of which 468 (42%) were cardiovascular deaths, 229 (20%) were infection-related deaths, and 141 (12%) were malignancy-related deaths.

Multivariable survival analyses accounting for intra-region correlation revealed that VDRA use was significantly associated with lower rates of infection: and malignancy-related deaths [subhazard ratio 0.62 (95% CI, 0.52 to 0.73) and 0.70 (95% CI, 0.50 to 0.97), respectively] but not with cardiovascular death [subhazard ratio 0.86 (95% CI, 0.72 to 1.04)]. Future randomized clinical trials with a sufficient sample size and an adequate follow-up period are warranted to test the clinical effectiveness of VDRA on infection and malignancy, rather than cardiovascular disease, among dialysis patients.

Publication and source details

Original title: Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching

Yoshitsugu Obi; Takayuki Hamano; Atsushi Wada; Yoshiharu Tsubakihara; The Committee of Renal Data Registry of the Japanese Society for Dialysis TherapyNakaiShigeru6HanafusaNorio7MasakaneIkuto8ItamiNoritomo9YamagataKunihiro10ShinodaToshio11KazamaJunichiro James12WatanabeYuzo13ShigematsuTakashi14MarubayashiSeiji15MoritaOsamu16KimataNaoki17WakaiKenji18OgataSatoshi19IsekiKunitoshi20YamamotoKeiichi21ShintaniAyumu22

Scientific Reports · 2017

a hamatea@kid.med.osaka-u.ac.jp
*

Present address: Division of Nephrology and Hypertension, University of California Irvine, Orange, CA 92868, USA.

†

These authors contributed equally to this work.

Copyright © 2017, The Author(s)2017The Author(s)https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T05:41:23.069401+00:00

DOI: 10.1038/srep41170 · PMC5282519